MA30421B1 - Pyrrolidinones substituees par un piperidinyle en tant qu'inhibiteurs de la 11-bêta-hydroxysteroïde deshydrogenase 1 - Google Patents

Pyrrolidinones substituees par un piperidinyle en tant qu'inhibiteurs de la 11-bêta-hydroxysteroïde deshydrogenase 1

Info

Publication number
MA30421B1
MA30421B1 MA31397A MA31397A MA30421B1 MA 30421 B1 MA30421 B1 MA 30421B1 MA 31397 A MA31397 A MA 31397A MA 31397 A MA31397 A MA 31397A MA 30421 B1 MA30421 B1 MA 30421B1
Authority
MA
Morocco
Prior art keywords
beta
piperidinyl
inhibitors
compounds
hydroxysteroid dehydrogenase
Prior art date
Application number
MA31397A
Other languages
English (en)
Inventor
Owen Brendan Wallace
Yanping Xu
Jeremy Schulenburg York
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA30421B1 publication Critical patent/MA30421B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention a pour objet de nouveaux composés de Formule I : ( I ) d'activité antagoniste vis-à-vis de la 11-Bêta-HSD de type 1, ainsi que des méthodes de synthèse de tels composés. Dans un autre mode d'application, la présente invention concerne des compositions pharmaceutiques comprenant des composés de Formule I, ainsi que des méthodes d'utilisation des composés et des compositions dans le traitement du diabète, de l'hyperglycémie, de l'obésité, de l'hypertension, de l'hyperlipidémie, du syndrome métabolique et d'autres états pathologiques associés à l'activité de la 11-Bêta-HSD de type 1. X-17433 PCT -1-
MA31397A 2006-04-28 2008-11-20 Pyrrolidinones substituees par un piperidinyle en tant qu'inhibiteurs de la 11-bêta-hydroxysteroïde deshydrogenase 1 MA30421B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79611206P 2006-04-28 2006-04-28

Publications (1)

Publication Number Publication Date
MA30421B1 true MA30421B1 (fr) 2009-05-04

Family

ID=38421166

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31397A MA30421B1 (fr) 2006-04-28 2008-11-20 Pyrrolidinones substituees par un piperidinyle en tant qu'inhibiteurs de la 11-bêta-hydroxysteroïde deshydrogenase 1

Country Status (23)

Country Link
US (1) US7829582B2 (fr)
EP (1) EP2049513B1 (fr)
JP (1) JP5225980B2 (fr)
KR (1) KR101060016B1 (fr)
CN (1) CN101448816B (fr)
AT (1) ATE542811T1 (fr)
AU (1) AU2007244742B2 (fr)
BR (1) BRPI0710469A2 (fr)
CA (1) CA2650627C (fr)
CY (1) CY1112466T1 (fr)
DK (1) DK2049513T3 (fr)
EA (1) EA014719B1 (fr)
EC (1) ECSP088849A (fr)
IL (1) IL194879A0 (fr)
MA (1) MA30421B1 (fr)
MX (1) MX2008013844A (fr)
NO (1) NO20084874L (fr)
PL (1) PL2049513T3 (fr)
PT (1) PT2049513E (fr)
SI (1) SI2049513T1 (fr)
TN (1) TNSN08432A1 (fr)
WO (1) WO2007127901A1 (fr)
ZA (1) ZA200808816B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA015675B1 (ru) 2006-04-21 2011-10-31 Эли Лилли Энд Компани Производные циклогексилпиразол-лактама в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1
CN101541747B (zh) * 2006-04-21 2012-11-14 伊莱利利公司 作为11-β-羟基甾族化合物脱氢酶1的抑制剂的联苯基酰胺内酰胺衍生物
BRPI0710273A2 (pt) 2006-04-21 2011-08-09 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, intermediário
SI2021336T1 (sl) 2006-04-24 2010-11-30 Lilly Co Eli Inhibitorji beta hidroksisteroid dehidrogenaze
CA2649111C (fr) 2006-04-24 2013-09-10 Eli Lilly And Company Pyrrolidinones substtuees a la cyclohexyle comme inhibiteurs de la 11-beta-hydroxysteroide dehydrogenase de type 1
EA016959B1 (ru) 2006-04-24 2012-08-30 Эли Лилли Энд Компани Замещенные пирролидиноны в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1 типа
JP5324427B2 (ja) 2006-04-25 2013-10-23 イーライ リリー アンド カンパニー １１−β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤
WO2007127726A2 (fr) 2006-04-25 2007-11-08 Eli Lilly And Company Inhibiteurs de la 11-bêta-hydroxystéroïde déshydrogénase 1
EP2016071B1 (fr) 2006-04-25 2013-07-24 Eli Lilly And Company Inhibiteurs de la 11-bêta-hydroxystéroïde déshydrogénase 1
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
EP2243479A3 (fr) 2009-04-20 2011-01-19 Abbott Laboratories Nouvel amide et dérivés d'amidine et utilisations associées
WO2011068927A2 (fr) * 2009-12-04 2011-06-09 Abbott Laboratories Inhibiteurs de la 11-β-hydroxystéroïde déshydrogénase de type 1 (11b-hsd1) et leurs utilisations
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
WO2011157827A1 (fr) 2010-06-18 2011-12-22 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
EP2683705B1 (fr) 2011-03-08 2015-04-22 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2683700B1 (fr) 2011-03-08 2015-02-18 Sanofi Dérivés d'oxathiazine tétra-substitués, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
KR101593493B1 (ko) 2014-10-28 2016-02-18 주식회사 아이에스티이 대면적 유리기판 열처리 장치

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050051691A (ko) * 2002-10-11 2005-06-01 아스트라제네카 아베 1,4-이치환 피페리딘 유도체 및 11-베타ｈｓｄ1억제제로서의 이들의 용도
WO2004056744A1 (fr) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides utilises comme inhibiteurs de la hydroxysteroide deshydrogenase
CN101001836B (zh) 2004-05-07 2010-12-22 詹森药业有限公司 作为11-β羟基类固醇脱氢酶抑制剂的吡咯烷-2-酮和哌啶-2-酮衍生物
EP1747198B1 (fr) 2004-05-07 2008-06-04 Janssen Pharmaceutica N.V. Utilisation de derives d'adamantyle pyrrolidin-2-one comme inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase
EP1802623A1 (fr) 2004-10-12 2007-07-04 Novo Nordisk A/S Composes spiro actifs du type a- hydroxysteroide deshydrogenase de type 1
PL1807072T3 (pl) * 2004-10-29 2009-06-30 Lilly Co Eli Cykloalkilowe pochodne laktamów jako inhibitory 11-ß-HSD1
TWI400239B (zh) 2004-11-10 2013-07-01 Incyte Corp 內醯胺化合物及其作為醫藥品之用途
DE602005007934D1 (de) 2004-12-20 2008-08-14 Lilly Co Eli Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
US7834194B2 (en) 2004-12-21 2010-11-16 Eli Lilly And Company Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
JPWO2006104280A1 (ja) * 2005-03-31 2008-09-11 武田薬品工業株式会社 糖尿病の予防・治療剤
US7998959B2 (en) 2006-01-12 2011-08-16 Incyte Corporation Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
CN101541747B (zh) 2006-04-21 2012-11-14 伊莱利利公司 作为11-β-羟基甾族化合物脱氢酶1的抑制剂的联苯基酰胺内酰胺衍生物
BRPI0710273A2 (pt) 2006-04-21 2011-08-09 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, intermediário
EA015675B1 (ru) 2006-04-21 2011-10-31 Эли Лилли Энд Компани Производные циклогексилпиразол-лактама в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1
EA016959B1 (ru) 2006-04-24 2012-08-30 Эли Лилли Энд Компани Замещенные пирролидиноны в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1 типа
SI2021336T1 (sl) 2006-04-24 2010-11-30 Lilly Co Eli Inhibitorji beta hidroksisteroid dehidrogenaze
CA2649111C (fr) 2006-04-24 2013-09-10 Eli Lilly And Company Pyrrolidinones substtuees a la cyclohexyle comme inhibiteurs de la 11-beta-hydroxysteroide dehydrogenase de type 1
WO2007127726A2 (fr) 2006-04-25 2007-11-08 Eli Lilly And Company Inhibiteurs de la 11-bêta-hydroxystéroïde déshydrogénase 1
EP2016071B1 (fr) 2006-04-25 2013-07-24 Eli Lilly And Company Inhibiteurs de la 11-bêta-hydroxystéroïde déshydrogénase 1
JP5324427B2 (ja) 2006-04-25 2013-10-23 イーライ リリー アンド カンパニー １１−β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤
CL2008001839A1 (es) 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.

Also Published As

Publication number Publication date
US7829582B2 (en) 2010-11-09
ECSP088849A (es) 2008-11-27
ATE542811T1 (de) 2012-02-15
AU2007244742A1 (en) 2007-11-08
KR101060016B1 (ko) 2011-08-29
EP2049513B1 (fr) 2012-01-25
BRPI0710469A2 (pt) 2011-08-16
PT2049513E (pt) 2012-03-20
CY1112466T1 (el) 2015-12-09
NO20084874L (no) 2008-11-19
CA2650627A1 (fr) 2007-11-08
MX2008013844A (es) 2008-11-10
SI2049513T1 (sl) 2012-04-30
EP2049513A1 (fr) 2009-04-22
CN101448816A (zh) 2009-06-03
JP5225980B2 (ja) 2013-07-03
CA2650627C (fr) 2013-07-16
EA014719B1 (ru) 2011-02-28
ZA200808816B (en) 2009-12-30
IL194879A0 (en) 2009-08-03
JP2009535362A (ja) 2009-10-01
DK2049513T3 (da) 2012-02-27
KR20090007371A (ko) 2009-01-16
WO2007127901A1 (fr) 2007-11-08
TNSN08432A1 (en) 2010-04-14
EA200870489A1 (ru) 2009-04-28
CN101448816B (zh) 2013-08-07
PL2049513T3 (pl) 2012-06-29
US20090088430A1 (en) 2009-04-02
AU2007244742B2 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
MA30421B1 (fr) Pyrrolidinones substituees par un piperidinyle en tant qu'inhibiteurs de la 11-bêta-hydroxysteroïde deshydrogenase 1
MA30476B1 (fr) Derives de type cyclohexylpyrazole-lactame comme inhibiteurs de la 11-beta-hydroxysteroïde deshydrogenase de type 1
MA30686B1 (fr) Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase.
DE602007007614D1 (de) Substituierte pyrrolidinone als hemmer von 11-beta-hydroxysteroiddehydrogenase 1
ATE543798T1 (de) Cyclohexyl-substituierte pyrrolidinone als hemmer von 11-beta-hydroxysteroiddehydrogenase 1
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
ATE471311T1 (de) Inhibitoren von11-beta- hydroxysteroiddehydrogenase 1
EA200870476A1 (ru) Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1
ATE455110T1 (de) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
MA32468B1 (fr) Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
ATE484505T1 (de) 5-sulfanylmethylä1,2,4ütriazolä1,5-aüpyrimidin- - olderivate als cxcr2-antagonisten
EA200970170A1 (ru) Производные 4-триметиламмоний-3-аминобутирата и 4-триметилфосфоний-3-аминобутирата как ингибиторы срт
MA33254B1 (fr) Applications thérapeutiques dans le domaine cardiovasculaire de dérivés de quinazolinedione